🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Pomalidomide

Also listed in trial records as Pomalyst
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 50 trials in our USA, China, UK, India and Ireland registers that name Pomalidomide as an intervention. Synced 24 Sep 2026
50Trials tracked
30Recruiting now
26Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards

Pomalidomide is named as a drug or biological intervention in 50 clinical trials in our USA, China, UK, India and Ireland trial registers, 30 of which are recruiting. Lead sponsors include Janssen Research & Development, LLC (10), AbbVie (5) and GlaxoSmithKline (4). Registered phases: Phase 3, Phase 1, Phase 1/2, Phase 2 and Not applicable. Conditions studied include Multiple Myeloma; Relapsed or Refractory Multiple Myeloma; Relapsed or Refractory Multiple Myeloma (RRMM).

01

Clinical trials of Pomalidomide

50 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT05020236 A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Recruiting Pfizer UK, USA, China
NCT05519085 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ClinicalTrials.gov ↗)
Relapsed or Refractory Multiple Myeloma
 Phase 3 Recruiting Celgene Ireland, UK, USA, India, China
NCT05730036 A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed Refractory Multiple Myeloma (RRMM)
 Phase 3 Recruiting Regeneron Pharmaceuticals UK, USA
NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
 Phase 3 Recruiting Pfizer UK, USA, China
NCT06464991 A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Recruiting Nanjing IASO Biotechnology Co., Ltd. China
NCT06615479 A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
 Phase 3 Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company UK, USA, China
NCT07138209 A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed or Refractory Multiple Myeloma
 Phase 3 Recruiting Qilu Pharmaceutical Co., Ltd. China
NCT07222761 A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (ClinicalTrials.gov ↗)
Relapsed and/or Refractory Multiple Myeloma (RRMM)
 Phase 3 Recruiting Regeneron Pharmaceuticals UK, USA
NCT07391657 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (ClinicalTrials.gov ↗)
Relapsed Refractory Multiple Myeloma
 Phase 3 Recruiting AstraZeneca UK, USA, China
NCT07452198 A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Recruiting Genrix (Shanghai) Biopharmaceutical Co., Ltd. China
NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Recruiting Hoffmann-La Roche USA, China
NCT07579234 A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed or Refractory Multiple Myeloma (RRMM)
 Phase 3 Recruiting Shandong New Time Pharmaceutical Co., LTD China
NCT07623798 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 (ClinicalTrials.gov ↗)
Relapsed or Refractory Multiple Myeloma
 Phase 3 Recruiting Innovent Biologics (Suzhou) Co. Ltd. China
NCT05348213 Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Diffuse Large B Cell Lymphoma
 Phase 2 Recruiting Ruijin Hospital China
NCT06342466 Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis (ClinicalTrials.gov ↗)
Systemic Amyloidosis
 Phase 2 Recruiting Jin Lu, MD China
NCT07018050 Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed or Refractory Multiple Myeloma
 Phase 2 Recruiting Qilu Pharmaceutical Co., Ltd. China
NCT07096778 Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
 Phase 2 Recruiting CellCentric Ltd. UK, USA
NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 2 Recruiting GlaxoSmithKline USA
NCT02343042 Selinexor and Backbone Treatments of Multiple Myeloma Patients (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1/2 Recruiting Karyopharm Therapeutics Inc USA
NCT04068597 Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma
 Phase 1/2 Recruiting CellCentric Ltd. UK, USA
NCT04643002 Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (ClinicalTrials.gov ↗)
Plasma Cell Myeloma Refractory
 Phase 1/2 Recruiting Sanofi USA
NCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed/Refractory Multiple Myeloma
 Phase 1/2 Recruiting BeOne Medicines UK, USA, China
NCT05714839 A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1/2 Recruiting GlaxoSmithKline UK, USA, China
NCT06106945 AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Multiple Myeloma
 Phase 1/2 Recruiting AstraZeneca USA, China
NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1/2 Recruiting AbbVie UK, USA
NCT04910568 A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1 Recruiting Genentech, Inc. UK, USA
NCT05137054 A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1 Recruiting Regeneron Pharmaceuticals USA
NCT05651932 A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma, Myeloma, Myeloma Multiple
 Phase 1 Recruiting K36 Therapeutics, Inc. USA
NCT06768489 A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
 Phase 1 Recruiting Janssen Research & Development, LLC USA
NCT07257510 Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma (ClinicalTrials.gov ↗)
Mantle Cell Lymphoma (MCL), POZ
 Not applicable Recruiting Peking University Third Hospital China
NCT07569757 Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Not yet open Chia Tai Tianqing Pharmaceutical Group Co., Ltd. China
NCT07728188 A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
 Phase 3 Not yet open AbbVie UK, USA
NCT05669989 International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Plasma Cell Myeloma
 Phase 2 By invitation Sanofi USA, China
NCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed AbbVie UK, USA, China
NCT04181827 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA
NCT04484623 Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed GlaxoSmithKline UK, USA, China
NCT05083169 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, China
NCT05405166 SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Plasma Cell Myeloma Recurrent
 Phase 3 Active, closed Sanofi UK, USA, China
NCT05438043 A Study of Daratumumab (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, China
NCT05455320 A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, China
NCT05572515 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed or Refractory Multiple Myeloma
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, India, China
NCT06158841 Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed AbbVie UK, USA, China
NCT06208150 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Multiple Myeloma
 Phase 3 Active, closed Janssen Research & Development, LLC UK, USA, India, China
NCT06413498 A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
 Phase 3 Active, closed Kite, A Gilead Company UK, USA
NCT04126200 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1/2 Active, closed GlaxoSmithKline USA
NCT04108195 A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Multiple Myeloma
 Phase 1 Active, closed Janssen Research & Development, LLC USA
NCT04667663 CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
Multiple Myeloma
 Phase 1 Active, closed Cancer Trials Ireland Ireland
NCT04722146 A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1 Active, closed Janssen Research & Development, LLC UK, USA
NCT05050097 A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Multiple Myeloma
 Phase 1 Active, closed Janssen Research & Development, LLC UK, USA
NCT05259839 A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Relapsed/Refractory Multiple Myeloma
 Phase 1 Active, closed AbbVie USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

23 conditions
Condition (as registered)Trials
Multiple Myeloma30
Relapsed or Refractory Multiple Myeloma6
Relapsed or Refractory Multiple Myeloma (RRMM)2
Relapsed/Refractory Multiple Myeloma2
Haematological Malignancy1
Acute Myeloid Leukemia1
Non Hodgkin Lymphoma1
Multiple Myeloma Refractory1
Multiple Myeloma in Relapse1
Plasma Cell Myeloma Recurrent1
Relapsed and/or Refractory Multiple Myeloma (RRMM)1
Relapsed Refractory Multiple Myeloma (RRMM)1
Relapsed Refractory Multiple Myeloma1
Plasma Cell Myeloma1
Smoldering Multiple Myeloma1
Immunoglobulin Light-chain Amyloidosis1
Plasma Cell Myeloma Refractory1
Myeloma1
Myeloma Multiple1
Mantle Cell Lymphoma (MCL)1
POZ1
Diffuse Large B Cell Lymphoma1
Systemic Amyloidosis1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Janssen Research & Development, LLC10
AbbVie5
GlaxoSmithKline4
Sanofi3
Regeneron Pharmaceuticals3
CellCentric Ltd.2
Pfizer2
AstraZeneca2
Qilu Pharmaceutical Co., Ltd.2
Cancer Trials Ireland1
Celgene1
Kite, A Gilead Company1
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company1
BeOne Medicines1
Genentech, Inc.1
Karyopharm Therapeutics Inc1
Hoffmann-La Roche1
K36 Therapeutics, Inc.1
Genrix (Shanghai) Biopharmaceutical Co., Ltd.1
Shandong New Time Pharmaceutical Co., LTD1
Peking University Third Hospital1
Nanjing IASO Biotechnology Co., Ltd.1
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1
Ruijin Hospital1
Innovent Biologics (Suzhou) Co. Ltd.1
Jin Lu, MD1
04

Trials by country register

RegisterPomalidomide trials
Clinical trials in USA39
Clinical trials in China29
Clinical trials in UK27
Clinical trials in India3
Clinical trials in Ireland2

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pomalidomide works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pomalidomide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.